Obermatt
See Similar Stocks →

Pacira BioSciences

NSQ:PCRX · US6951271005
PharmaceuticalsMedium

360

79
EV / EBIT96
Price / Owner Earnings47
Owner Earnings Yield77
Dividend Yield1
Price/Sales94
EV / Gross Profit87
Price/Book64
Return on Capital47
Cash Return on Capital80
Return on Equity46
EBIT Margin32
Gross Profitability81
Cash Conversion100
Accruals84
Owner Earnings Margin75
Sales growth51
Profit Growth75
Long-Term EPS Growth19
Reinvestment49
Price momentum32
Debt load32
Refinancing98
Debt Payback36
Liquidity69
Analyst ratings16
Opinion Changes50
Price Target Upside23
Market mood41
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Pacira BioSciences clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2006
Employees800
Websitepacira.com
ISINUS6951271005
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyPain ManagementOsteoporosisStem Cell TherapyCentral Nervous SystemSurgeryNeuroscienceDentistryOrthopaedicsGenetics

Description

Pacira BioSciences, Inc. (‘Pacira’) operates as a holding company for its California operating subsidiary named Pacira Pharmaceuticals, Inc. In February 2025, the company acquired GQ Bio Therapeutics GmbH, a privately held biopharmaceutical company…

Analysis

Hidden champion

Pacira BioSciences, Inc. fits the profile of a hidden champion, yet the market has not awarded it the premium its quality earns.

On valuation, the picture is attractive. The owner-earnings multiple stands at 10.6×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is adequate. The company scores 12/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
81
2023202420252026

All-time high

100

Feb 2024

All-time low

40

Jan 2023

Average rank

74

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
94
57
46
30
Price/Earnings
33
90
75
63
Price/Book
64
61
50
38
Dividend Yield
1
1
1
1
Value (overall)
79
80
91
45

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Pacira BioSciences with its peers
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Bristol-Myers Squibb
NYQ:BMY
58
CountryUSA
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Liquidia Corporation
NAQ:LQDA
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Viatris
NSQ:VTRS
37
CountryUSA
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Grace Therapeutics
NAQ:GRCE
52
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Verrica Pharmaceuticals
NAQ:VRCA
55
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →